source
- Verastem reports robust response in pancreatic cancer subgroup where Revolution's drug laggedVerastem Oncology announced that its KRAS G12D‑targeting inhibitor VS‑7375 showed strong activity in a Phase 1/2 trial that includes patients with advanced solid tumors. In the pancreatic cancer co…
- Johnson & Johnson shares drop 6% after earnings meet forecasts but show weak medical device outlookJohnson & Johnson reported third‑quarter results that met Wall Street expectations and raised its 2026 financial guidance, yet the stock fell about 6% on the day. Analysts highlighted an underwhel…BioPharma Dive · 27d agoEarningsNegative